Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Investigational New Drugs

Volumn 34, Issue 3, 2016, Pages 347-354

  Shimizu, Toshio ^a   Seto, Takashi ^b   Hirai, Fumihiko ^b   Takenoyama, Mitsuhiro ^b   Nosaki, Kaname ^b   Tsurutani, Junji ^a   Kaneda, Hiroyasu ^a   Iwasa, Tsutomu ^a   Kawakami, Hisato ^a   Noguchi, Kazuo ^c   Shimamoto, Takashi ^c   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c Merck Sharp Dohm Res Labs Japan   (Japan)

Author keywords

Anti PD 1 therapy; PD L1; Pembrolizumab; Pharmacokinetics; Phase I study

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLYCYRRHETINIC ACID; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; THYROTROPIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN INFARCTION; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEHYDRATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; JAPANESE (PEOPLE); LIMIT OF QUANTITATION; MALAISE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; URTICARIA; WEIGHT REDUCTION; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 84961827143     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0347-6     Document Type: Article

References (31)

1. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28:4531–4538
2. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800
3. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116–126
4. Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257–1266
5. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242
6. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC et al (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13:1757–1761
7. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H et al (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151–2157
8. Gao Q, Wang X-Y, Qiu S-J, Yamato I, Sho M, Nakajima Y et al (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15:971–979
9. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104:3360–3365
10. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28:682–688
11. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D et al (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182:5240–5249
12. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y et al (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15:971–979
13. Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739–745
14. Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K et al (2006) Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 42:268–274
15. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293–12297
16. Sznol M, Powderly JD, Smith DC, Brahmer JR, Drake CG, McDermott DF et al (2010) Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies [Abstract]. J Clin Oncol 28(Suppl):2506
17. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175
18. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M et al (2015) Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293
19. Ji Y, Li Y, Nebiyou Bekele B (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4:235–244
20. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
21. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26:1824–1829
22. Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697
23. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
24. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520
25. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128
26. Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu WJ et al. (2015) Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature [Meeting Abstract]. J Clin Oncol 33 (suppl; abstr 3001)
27. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918
28. Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford RF et al. (2014) Pembrolizumab (Pembro; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. Ann Oncol 25 (suppl 4): doi: 10.1093/annonc/mdu438.42
29. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
30. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109–1117
31. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. doi:10.1016/S0140-6736(15)01281-7